Again about carbonic anhydrase inhibitors: modern aspects of the use of ICA in ophthalmology
| Autor: | P.A. Bezdetko |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Archive of Ukrainian Ophthalmology. 9:64-71 |
| ISSN: | 2311-2999 2309-8147 |
| DOI: | 10.22141/2309-8147.9.2.2021.241511 |
| Popis: | For more than 70 years, the inhibitors of carbonic anhydrase (ICA) have been used in the treatment of glaucoma. Since 1995, topical forms of ICA have appeared among antiglaucoma drugs — dorzolamide, and since 1999 — brinzolamide. The hypotensive efficacy and safety of topical ICA gave rise to the widespread use of these drugs in the treatment of various forms of glaucoma. The peculiarities of the mechanism of action made it possible to create on their basis effective fixed combinations, which allow reducing the intraocular pressure by up to 40 % in patients with glaucoma. The attractiveness of the drug has expanded due to the effect of ICA on various tissues of the organ of vision. Thus, ICAs effectively improve the hemodynamics of the eye and optic nerve. The antioxidant activity of the drug makes it possible to expand the indications for its use in patients with vascular patho-logy of the retina and optic nerve. The biomechanical characte-ristics of the drug allowed its effective and safe use in the complex treatment of macular edema of various etiologies. The adjuvant use of topical ICAs expands the possibilities of anti-VEGF therapy in the treatment of macular edema of various etiologies. Features of the action of ICA on the endothelial pump function of the cornea made it possible to formulate the rules for the use of topical ICA in patients with an insufficient function of the corneal endothelium. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|